4th Cell Therapy for Autoimmune Disease Summit

Memo

As the autoimmune cell therapy field enters a pivotal phase of clinical and commercial development, the 4th Cell Therapy for Autoimmune Disease Summit returns as the industry's premier forum dedicated to accelerating the translation of next-generation cell therapies into transformative treatments for patients living with autoimmune diseases. Bringing together leading experts from biotech, pharma, academia, clinical research, and translational science, this summit provides a unique platform to explore the latest scientific breakthroughs, clinical successes, and strategic challenges shaping the future of autoimmune cell therapy.With highly anticipated clinical readouts expected across multiple therapeutic modalities, including CAR-T, regulatory T-cell (Treg), natural killer (NK), mesenchymal stromal cell (MSC), and emerging in vivo engineered cell therapies, the industry is rapidly progressing beyond proof-of-concept and toward scalable, commercially viable solutions. The summit offers attendees exclusive insights into how developers are optimizing safety, enhancing durability of response, improving patient accessibility, and advancing innovative immune reset strategies across a growing range of autoimmune indications.Over three days, delegates will hear directly from pioneering organizations including Artiva Biotherapeutics, Cabaletta Bio, Orca Bio, Kite Pharma, Mesoblast, Sail Biomedicines, Immuthera/PolTREG, CPTx, Overland Therapeutics, GentiBio, Quell Therapeutics, and many others that are driving the next generation of autoimmune cell therapy innovation. Speakers will share lessons learned from preclinical development, translational research, clinical trial execution, regulatory interactions, manufacturing scale-up, and commercialization planning, offering attendees a comprehensive view of the evolving landscape.The agenda features dedicated tracks focused on Preclinical Development and Translation and Clinical Development, enabling attendees to tailor their experience to their scientific and strategic priorities. Explore cutting-edge advancements in target discovery, translational modelling, immune profiling, biomarker development, and next-generation engineering approaches designed to improve efficacy and safety. Gain insight into how innovators are identifying new therapeutic targets beyond CD19, developing multi-mechanism and combination strategies, and leveraging AI-driven approaches to accelerate discovery and development.A major theme of this year's summit is the emergence of in vivo cell therapy, with industry pioneers showcasing novel RNA and DNA delivery technologies designed to engineer immune cells directly within patients. Attendees will examine the opportunities and challenges associated with these groundbreaking platforms, including advances in delivery technologies, scalability, manufacturing efficiency, and clinical translation. Sessions will highlight how in vivo approaches may redefine accessibility and unlock broader patient populations beyond traditional autologous therapies.Clinical development remains at the forefront of discussions as organizations present the latest data across autoimmune indications including lupus, type 1 diabetes, rheumatoid arthritis, neuromuscular diseases, and other severe autoimmune conditions. Learn how leading developers are evaluating response durability, improving patient selection, optimizing trial design, and generating long-term outcomes data to support regulatory approvals and broader adoption. Experts will also discuss evolving definitions of immune reset, disease stratification strategies, and the importance of translational biomarkers in guiding clinical decision-making.Beyond clinical innovation, the summit provides unique perspectives on the commercial realities that will determine the future success of autoimmune cell therapies. For the first time, attendees will gain valuable insights into commercialization pathways, pricing considerations, reimbursement challenges, manufacturing scalability, and market access strategies. Industry leaders will explore lessons learned from recent approvals and discuss how developers can successfully transition from clinical promise to commercial reality.Whether you are developing autologous, allogeneic, or in vivo therapies, seeking to advance translational research, optimize clinical development, secure investment, or prepare for commercialization, the 4th Cell Therapy for Autoimmune Disease Summit is your essential meeting point to stay ahead of the latest innovations and collaborate with the leaders shaping the future of autoimmune disease treatment. Join the global community advancing safer, more durable, and scalable cell therapies that have the potential to transform patient outcomes and redefine standards of care across autoimmune disease.URLs:Tickets: https://go.evvnt.com/3770279-2?pid=5569Brochure: https://go.evvnt.com/3770279-3?pid=5569Date and Time: On Tuesday December 01, 2026 at 9:00 am to Thursday December 03, 2026 at 4:00 pmVenue details: Hilton Philadelphia City Avenue, 4200 City Avenue, Philadelphia, Pennsylvania, 19131, United StatesPrices:Drug Developer Pricing - Conference + 2 Workshops: USD 4397.00,Drug Developer Pricing - Conference + 1 Workshop: USD 3748.00,Drug Developer Pricing - Conference Only: USD 3099.00,Academic and Small Biotech Pricing - Conference + 2 Workshops: USD 3797.00,Academic and Small Biotech Pricing - Conference + 1 Workshop: USD 3248.00,Academic and Small Biotech Pricing - Conference Only: USD 2699.00,Service Provider Pricing - Conference + 2 Workshops: USD 5397.00,Service Provider Pricing - Conference + 1 Workshop: USD 4648.00,Service Provider Pricing - Conference Only: USD 3899.00Speakers: Fred Aslan, President and Chief Executive Officer, Artiva Biotherapeutics, Teresa Montagut, Head of Clinical Development and Medical Affairs, Mesoblast, Edward Rebar, Chief Scientific Officer, CPTx, Srikanth Muppidi, Autonomic Disorders Specialist, Stanford University, Adria Carbo, Vice President and Head of Business Development, Orca Bio, Chloe Slichter, Director, Discovery Biology, Kite Pharma, Frank Borriello, Scientific Founder and Chief Executive Officer, Alloplex Biotherapeutics, Tom Thomas, Principal Investor, Newpath Partners, Mark Bach, Chief Medical Officer, GentiBio, Peter Merkel, Professor, Medicine Rheumatology, University of Pennsylvania, David Porter, Director, Cell Therapy and Transplant, University of Pennsylvania, Thomas Furmanak, Director, Translational Medicine, Cabaletta Bio, Ed Zhang, Co-Founder and Chief Executive Officer, Overland Therapeutics, Meredith Jackson, Scientific Program Officer, Lupus Research Alliance, Diego Miralles, President and Head of R and D, Artiva Biotherapeutics, Shawn Rose, Chief Medical Officer and Head of R and D, Nkarta, Anna-Maria Georgoudaki, Senior R and D Manager, Glycostem Therapeutics, Dan Shelly, Chief Business Development Officer, Immuthera / PolTREG, Jason Peng, Associate Principal Scientist, Cabaletta Bio, Nathalie Belmonte, Chief Science and Technical Officer, Quell Therapeutics, Michael Mingueneau, Senior Vice President, Immunology, Sail Biomedicines, Gary Gilkeson, Distinguished University Professor, Medical University of South Carolina, Thimmaiah Chendrimada, Founder, Able Sciences